Maplight Therapeutics (NASDAQ:MPLT) Posts Quarterly Earnings Results, Beats Expectations By $0.25 EPS

Maplight Therapeutics (NASDAQ:MPLT – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.22) by $0.25, FiscalAI reports.

Maplight Therapeutics Price Performance

MPLT opened at $7.25 on Monday. Maplight Therapeutics has a 12 month low of $6.06 and a 12 month high of $40.43. The stock has a market cap of $402.95 million and a P/E ratio of -0.17. The stock’s 50 day moving average price is $9.34 and its 200 day moving average price is $19.85.

Insider Activity

In other news, CFO Jonathan Gillis sold 10,167 shares of the stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $8.08, for a total value of $82,149.36. Following the completion of the transaction, the chief financial officer owned 142,315 shares of the company’s stock, valued at approximately $1,149,905.20. This represents a 6.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James Lillie sold 11,513 shares of the firm’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $8.08, for a total value of $93,025.04. Following the transaction, the insider directly owned 198,597 shares in the company, valued at $1,604,663.76. This trade represents a 5.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 122,974 shares of company stock worth $990,690 over the last ninety days. 3.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Maplight Therapeutics

Several institutional investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new position in shares of Maplight Therapeutics in the second quarter valued at approximately $36,741,000. Nan Fung Group Holdings Ltd acquired a new position in shares of Maplight Therapeutics during the second quarter valued at approximately $34,809,708. 5AM Venture Management LLC bought a new stake in Maplight Therapeutics during the second quarter worth approximately $34,048,394. Blue Owl Capital Holdings LP bought a new stake in Maplight Therapeutics during the second quarter worth approximately $26,161,000. Finally, Marshall Wace LLP raised its holdings in Maplight Therapeutics by 10,457.1% during the third quarter. Marshall Wace LLP now owns 612,310 shares of the company’s stock worth $6,239,000 after purchasing an additional 606,510 shares in the last quarter.

Analyst Upgrades and Downgrades

MPLT has been the subject of a number of recent research reports. Jefferies Financial Group restated a “buy” rating on shares of Maplight Therapeutics in a research note on Monday, July 27th. BMO Capital Markets started coverage on Maplight Therapeutics in a research report on Monday, July 20th. They issued an “outperform” rating and a $46.00 target price on the stock. UBS Group cut Maplight Therapeutics from a “buy” rating to a “neutral” rating and cut their target price for the company from $52.00 to $13.00 in a research note on Monday, August 10th. Weiss Ratings cut Maplight Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 23rd. Finally, Morgan Stanley downgraded shares of Maplight Therapeutics from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $34.00 to $21.00 in a report on Tuesday, July 28th. Four research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Maplight Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $29.50.

Check Out Our Latest Report on Maplight Therapeutics

Maplight Therapeutics Company Profile

(Get Free Report)

MapLight Therapeutics is a clinical-stage biopharmaceutical company developing medicines for people with serious brain disorders. Its research focuses on treatments intended to address symptoms that can be difficult to manage with existing therapies. The company’s investigational programs include ML-007 for schizophrenia and ML-004 for autism spectrum disorder. These candidates remain in development and are not approved medicines.

Read More

Earnings History for Maplight Therapeutics (NASDAQ:MPLT)

Receive News & Ratings for Maplight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maplight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.